Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 94Leukemia, Lymphocytic, Chronic, B-Cell 56Neoplasms 37Recurrence 28Lymphoma, Non-Hodgkin 25Myelodysplastic Syndromes 21Multiple Myeloma 18Leukemia 16Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 10Hematologic Neoplasms 10Lymphoma, Mantle-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid 6Lymphoma 5Chromosome 17 deletion 5Lymphoma, B-Cell 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2Hematologic Diseases 2GATA2 Deficiency 2

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × venetoclax × Clear all
NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

AbbVie

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡